Filoviridae Infections is an indication for drug development with over 150 pipeline drugs currently active. According to GlobalData, preregistered drugs for Filoviridae Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Filoviridae Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Filoviridae Infections overview

Filovirideae infections are caused by viruses in the family Filoviridae, which can cause severe hemorrhagic fever in humans and nonhuman primates. The family includes six genera: Cuevavirus, Dianlovirus, Ebolavirus, Marburgvirus, Striavirus, and Thamnovirus. The natural hosts of filoviruses are bats, but they can also infect other animals such as monkeys and pigs. Filoviruses are transmitted through direct contact with infected body fluids or tissues. They have high fatality rates and pose a serious threat to public health. There is no specific treatment or vaccine for filovirideae infections, but supportive care and infection prevention and control measures can reduce mortality and transmission.

For a complete picture of PTSR and LoA scores for drugs in Filoviridae Infections, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.